Scott J. Rodig, Ph.D., M.D.
This page shows the publications co-authored by Scott Rodig and David Dorfman.
Characteristic expression patterns of TCL1, CD38, and CD44 identify aggressive lymphomas harboring a MYC translocation. Am J Surg Pathol. 2008 Jan; 32(1):113-22.
BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum Pathol. 2005 Oct; 36(10):1113-9.
The CD45 isoform B220 identifies select subsets of human B cells and B-cell lymphoproliferative disorders. Hum Pathol. 2005 Jan; 36(1):51-7.
CCR6 is a functional chemokine receptor that serves to identify select B-cell non-Hodgkin's lymphomas. Hum Pathol. 2002 Dec; 33(12):1227-33.
Splendore-Hoeppli phenomenon. Arch Pathol Lab Med. 2001 Nov; 125(11):1515-6.
Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res. 2006 Dec 01; 12(23):7174-9.
Profile of CD103 expression in T-cell neoplasms: immunoreactivity is not restricted to enteropathy-associated T-cell lymphoma. Am J Surg Pathol. 2014 Nov; 38(11):1557-70.
Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project. Am J Surg Pathol. 2014 Jun; 38(6):768-75.
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014 Feb 27; 123(9):1293-6.
Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. PLoS One. 2013; 8(6):e67306.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.